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This data paper contains information about the in vivo model for
peritoneal implants used in the paper “Tumor-environment biomi-
metics delay peritoneal metastasis formation by deceiving and redir-
ecting disseminated cancer cells” (De Vlieghere et al., 2015) [1]. A
double in vivo selection of SK-OV-3 Luc human ovarian cancer cell line
was used to create SK-OV-3 Luc IP1 and SK-OV-3 Luc IP2 cell lines. This
data paper shows functional activities of the three cell lines in vitro and
in vivo. Phase-contrast images show the morphology of these cells,
metabolic and luciferase activity has been determined. Survival data of
mice peritoneally injected with SK-OV-3 Luc or SK-OV-3 Luc IP2 is
available with H&E histology of the peritoneal implants. Tumor growth
curves and bioluminescent images of mice inoculated with a different
number of SK-OV-3 Luc IP2 cells are also included.
& 2016 The Authors. Published by Elsevier Inc. This is an open access
article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Speciﬁcations tableubject area Biology
Cancer biologyvier Inc. This is an open access article under the CC BY license
Bracke), Olivier.dewever@ugent.be (O. De Wever).
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ject area
ype of data Phase contrast images, graphs, histology, bioluminescence images
ow data was
acquired Phase contrast microscope ( DMI 3000B,Leica, Wetzlar, Germany)
 Plate reader (Paradigm, Molecular Devices, Sunnyvale, CA, USA)
 Light microscope (DM750,Leica, Wetzlar, Germany)
 Bioluminescent imager (IVIS, PerklinElmer, Waltham, MA, USA)ata format Analyzed
xperimental
factorsSK-OV-3-Luc cells were inoculated intraperitoneally in immune deﬁcient
female mice Swiss/nu to select for a population that more efﬁciently forms
peritoneal implants.xperimental
featuresThe created cell line SK-OV-3 Luc IP1 and SK-OV-3 Luc IP2 are compared with
the parental cell line SK-OV-3 Lucata source
locationGhent, Belgiumata accessibility The data is available with this articleDValue of the data
 This data shows intraperitoneal tumor formation with low cell inoculation after in vivo selection of
SK-OV-3.
 This method can be applied to other cancer cell lines to increase metastasis take rate even with
lower inoculation numbers.
 These data provides growth curves, survival data and histology about the SK-OV-3 Luc (IP2) in vivo
model for peritoneal implants, providing researchers with a references for their in vivo studies.1. Data
Intraperitoneal injection (IP) of SK-OV-3 (Luc) cells is an established in vivo model for the devel-
opment of peritoneal ovarian tumor implants. Usually inoculation numbers of 1–2106 SK-OV-3
(Luc) are used [2–4]. The IP injection of 1106 SK-OV-3 Luc cells gives a 100% tumor take with an
average survival time of over 2 months (Fig. 3B) [3]. To better mimic the patient situation where an
initial low number of aggressive disseminated cells can form extensive peritoneal metastasis a
xenograft mouse model with inoculation of low numbers of cancer cells is needed. in vivo selection
has been successfully used to increase the metastatic potential of MDA-MB-231 [5]. These data
describe the successive in vivo selection of the SK-OV-3 Luc cell line. Tumor implants of SK-OV-3 Luc
bearing mice are re-cultured in vitro to increase in vivo peritoneal implant formation. After successive
in vivo selection, IP inoculation of 10-to-20X lower number (1105) of SK-OV-3 Luc IP2 is sufﬁcient to
form peritoneal implants this model has been applied successfully [1].2. Experimental design, materials and methods
2.1. Cell culture conditions
SK-OV-3 is a human ovarian cancer cell line (ATCC number: HTB-77). SK-OV-3 Luc (Luciferase
positive SK-OV-3 cells) were prepared by pFL4.76 plasmid transfection and selection (Promega, Lei-
den, The Nederlands). SK-OV-3 Luc (IP1/2) were maintained in Dulbecco’s modiﬁed Eagle’s medium
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and incubated at 37 °C with 10% CO2 in air.
2.2. in vivo selection
Animal experiments were conducted accordance with the local ethics committee (Ghent Uni-
versity Hospital). 1106 SK-OV-3-Luc cells were inoculated intraperitoneally in immunodeﬁcient
female Swiss/nu mice (Charles River, Chatillon-sur-Chalaronne, France) to isolate populations that
form peritoneal implants. Tumor implants were collected in saline. The implants were cut into small
pieces (1 mm) and dissociated by de gentleMACS Dissociator (Miltenyi Biotec, Teterow, Germany) in
the presences of 1 mg/ml collagenase from Clostridium histolyticum (Sigma-Aldrich) in PBSDþ . The
mixture was cleared through a cell strainer (70 mm) and the homogenized single cell suspension was
expanded in culture by seeding in DMEM 10% FBS. After 24 h, non-adhered cells were removed and
the medium was refreshed; the resulting culture was maintained as the parental cell line. Each
subsequent intraperitoneal metastatic generation is designated IP1, IP2. Fig. 1 shows a schematic with
the different stages of the in vivo selection. Fig. 2A shows phase-contrast images of the three cell lines
cultured on plastic
2.3. Sort tandem repeat (SRT) proﬁling
SRT-proﬁling was conducted on the SK-OV-3, SK-OV-3 Luc and SK-OV-3 Luc IP2 cell lines to
conﬁrm the identity of the cell lines. 9 DNA sites were proﬁled and the alleles were identical between
the three cell lines and to the proﬁle published by ATCC (Amelogenin: X; CSF1PO: 11; D13S317: 8,11;
D16S539: 12; D5S818: 11; D7S820: 13,14; THO1: 9,9.3; TPOX: 8,11; vWA: 17,18) [6].
2.4. Metabolic activity analysis: 3-4,5-Dimethylthiazolyl-2-2,5-Diphenyltetrazolium Bromide (MTT)
A single cell suspension of 4104 SK-OV-3 Luc or SK-OV-3 Luc IP1 cells per well, were seeded in a
96-well plate. After 96 h, MTT analysis was performed. Brieﬂy, the culture medium was replaced by
100 μl culture medium containing 1 mg/ml MTT. Following 2 h incubation at 37 °C, MTT-containing
medium was removed and 150 μl of dimethylsulfoxide (DMSO) was added to dissolve formazan
crystals. Absorbance was measured at 570 nm and background measured at 650 nm, with a plate
reader (Paradigm, Molecular Devices). Fig. 2B shows the average absorbance value (n¼3) of 6 inde-
pendent metabolic activity analysis 96 h after seeding 4104 SK-OV-3 Luc or SK-OV-3 Luc IP1.
2.5. in vitro bioluminescence
A single cell suspension of SK-OV-3 Luc, SK-OV-3 Luc IP1 and SK-OV-3-Luc-IP2 cells were seeded in
a 96-well plate in different cell numbers (125, 250, 500, 1000 and 2000 cells per well). Cells were
allowed to adhere for 2 h, just before luciferase activity was measured with IVIS (PerkinElmer),
150 mg/ml D-Luciferin, ﬁreﬂy (Perkin-Elmer) was added. Fig. 2C shows the average bioluminescence
value of three replicates.
2.6. in vivo survival analysis
Animal experiments were conducted in accordance with the local ethics committee (Ghent Uni-
versity Hospital). Immune deﬁcient female Swiss/nu mice were inoculated intraperitoneally with
1106 SK-OV-3-Luc or SK-OV-3-Luc-IP2 cells. Mice were monitored and from the ﬁrst visual signs of
advanced carcinomatosis (decrease in weight or increase in abdominal circumference) the mice had
reached their end-point and were sacriﬁced. Peritoneal organs were embedded in parafﬁn before
standard hematoxylin and eosin (H&E) staining was conducted. Fig. 3A shows H&E staining of the
peritoneal tumor implants, B shows comparative survival curves.
Fig. 1. Schematic showing the successive stages of the in vivo selection with indication of the different in vitro and in vivo
assays conducted.
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Immune deﬁcient female Swiss/nu mice were inoculated intraperitoneally with 1106, 0.5106,
0.25106 and 0.1106 SK-OV-3 Luc IP2 cancer cells. Tumor growth was monitored by weekly biolumi-
nescence imaging (BLI). Fig. 4 shows the different growth curves (A) and the bioluminescence images (B).Fig. 2. (A) Phase-contrast images of SK-OV-3 Luc, SK-OV-3 Luc IP1 and SK-OV-3-Luc-IP2 cultured cell cultured treated culture
ﬂasks. (B) Metabolic activity analysis (MTT): the average absorbance value (n¼3) of 6 independent metabolic activity analysis
96 h after seeding 4104 SK-OV-3 Luc or SK-OV-3 Luc IP1. (C) in vitro average bioluminescence (n¼3) of SK-OV-3 Luc, SK-OV-3
Luc IP1 and SK-OV-3-Luc-IP2 for 125, 250, 500, 1000 and 2000 cells, 2 h after seeding.
Fig. 3. (A) H&E staining's of peritoneal implants at the site of peritoneum, mesentery, pancreas and diaphragm of SK-OV-3 Luc or
SK-OV-3 Luc IP2 tumors. (B) Comparative survival curves of mice IP injected with 1106 SK-OV-3 Luc and SK-OV-3 Luc IP2 cells.
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Fig. 4. Growth curves (A) and BLI (B) of mice inoculated with 1106, 0.5106, 0.25106 or 0.1106 SK-OV-3 Luc IP2 cells
(n¼3).
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